XL-647

CAS No. 781613-23-8

XL-647 ( Tesevatinib;EXEL-7647;KD-019 )

Catalog No. M15946 CAS No. 781613-23-8

XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 142 Get Quote
5MG 224 Get Quote
10MG 434 Get Quote
25MG 710 Get Quote
50MG 972 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    XL-647
  • Note
    Research use only, not for human use.
  • Brief Description
    XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
  • Description
    XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively; shows no inhibition on IGF1R and InsR, also is inactive against a panel of 55 serine-threonine kinases (including CDKs, stress-activated protein kinases, and PKC isoforms; inhibits WT and mutant EGFR phosphorylation in cells with IC50 of 5 and 74 nM, inhibits mutant EGFR resistant to gefitinib and erlotinib, inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors double mutation L858R/T790M; inhibits H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density in vivo.Lung Cancer Phase 3 Clinical
  • Synonyms
    Tesevatinib;EXEL-7647;KD-019
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    781613-23-8
  • Formula Weight
    491.40
  • Molecular Formula
    C24H25Cl2FN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 30 mg/mL
  • SMILES
    O=C(NC1=CC=C(CCN2CC3=C(C=C(OC)C(OC)=C3)CC2)C=C1)C4=CC=CC(/C=C(C(N(C)/C5=C\C6=CC=CC=C6)=O)\NC5=O)=C4
  • Chemical Name
    4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aα,5β,6aα)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pietanza MC, et al. J Thorac Oncol. 2012 Jan;7(1):219-26.
2. Gendreau SB, et al. Clin Cancer Res. 2007 Jun 15;13(12):3713-23.
molnova catalog
related products
  • EGFR-IN-7

    EGFR-IN-7 is a selective and potent EGFR kinase inhibitor.TQB3804 displayed potent enzymatic activities for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, and EGFRL858R/T790M with IC50 of 0.46, 0.13, 0.26, and 0.19 nM respectively, and has similar enzymatic activity for EGFRWT (IC50 = 1.07) to Osimertinib.

  • Withanolide A

    Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans.

  • EGFR/ErbB2 Inhibitor

    EGFR/ErbB2 Inhibitor is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)